Structure and biosynthetic implication of (S)-NHAB, a novel shunt product, from a disruptant of the actVI-ORFA gene for actinorhodin biosynthesis in Streptomyces coelicolor A3(2)

A single-domain small protein Med-ORF10 regulates the production of antitumour agent medermycin in Streptomyces

Med-ORF10, a single-domain protein with unknown function encoded by a gene located in a gene cluster responsible for the biosynthesis of a novel antitumour antibiotic medermycin, shares high homology to a group of small proteins widely distributed in many aromatic polyketide antibiotic pathways. This group of proteins contain a nuclear transport factor-2 (NTF-2) domain and appear to undergo an evolutionary divergence in their functions. Gene knockout and interspecies complementation suggested that Med-ORF10 plays a regulatory role in medermycin biosynthetic pathway. Overexpression of med-ORF10 in its wild-type strain led to significant increase of medermycin production. It was also shown by qRT-PCR and Western blot that Med-ORF10 controls the expression of genes encoding tailoring enzymes involved in medermycin biosynthesis. Transcriptome analysis and qRT-PCR revealed that Med-ORF10 has pleiotropic effects on more targets. However, there is no similar conserved domain available in Med-ORF10 compared to those of mechanistically known regulatory proteins; meanwhile, no direct interaction between Med-ORF10 and its target promoter DNA was detected via gel shift assay. All these studies suggest that Med-ORF10 regulates medermycin biosynthesis probably via an indirect mode.

Structural characterization of three noncanonical NTF2-like superfamily proteins: implications for polyketide biosynthesis

Proteins belonging to the NTF2-like superfamily are present in the biosynthetic pathways of numerous polyketide natural products, such as anthracyclins and benzoisochromanequinones. Some have been found to be bona fide polyketide cyclases, but many of them have roles that are currently unknown. Here, the X-ray crystal structures of three NTF2-like proteins of unknown function are reported: those of ActVI-ORFA from Streptomyces coelicolor A3(2) and its homologs Caci_6494, a protein from an uncharacterized biosynthetic cluster in Catenulispora acidiphila, and Aln2 from Streptomyces sp. CM020, a protein in the biosynthetic pathway of alnumycin. The presence of a solvent-accessible cavity and the conservation of the His/Asp dyad that is characteristic of many polyketide cyclases suggest a potential enzymatic role for these enzymes in polyketide biosynthesis.

Unified Approach toward Syntheses of Juglomycins and Their Derivatives

A unified and common intermediate strategy for syntheses of juglomycins and their derivatives is reported. The use of a 1,4-dimethoxynaphthalene derivative as a key intermediate enabled easy access to various juglomycin derivatives. In this study, juglomycins A-D, juglomycin C amide, khatmiamycin and its 4-epimer, and the structure proposed for juglomycin Z were synthesized from this intermediate. The absolute configuration of natural khatmiamycin has been established to be 3R,4R through our synthesis. Unfortunately, the spectroscopic data for synthetic juglomycin Z were not consistent with the data reported for the natural one, strongly suggesting a structural misassignment.

Khatmiamycin, a motility inhibitor and zoosporicide against the grapevine downy mildew pathogen Plasmopara viticola from Streptomyces sp. ANK313

In the course of our screening for anti-peronosporomycetal agents, we isolated a new compound khatmiamycin (1), together with five known metabolites, GTRI-02 (3), 4-ethyl-5-methyl-heptanamide (4), aloesaponarin II (5), LL-C10037α (6) and LL-C10037β (7) from the culture broth of a terrestrial Streptomyces sp. ANK313. The structures of these metabolites were assigned on the basis of their spectroscopic data. Khatmiamycin (1) exhibited potent motility inhibitory (100%) and lytic (83±7%) activities against zoospores of the grapevine downy mildew pathogen Plasmopara viticola at 10 μg ml(-1), followed by compounds 5 (MIC 25 μg ml(-1)), 7, 6, 3 in the order of decreasing activity. Khatmiamycin (1) also showed potent antibacterial activity against Staphylococcus aureus and Streptomyces viridochromogenes (Tü57) by causing inhibition zones of 11 and 14 mm diameter, respectively, at the dose of 40 μg per disk. This is the first report on motility inhibitory and lytic activities of metabolites from a terrestrial Streptomyces species against the zoospores of downy mildew pathogen P. viticola.

Possible involvement of ActVI-ORFA in transcriptional regulation of actVI tailoring-step genes for actinorhodin biosynthesis

The actinorhodin biosynthetic gene (act) cluster in Streptomyces coelicolor carries a functionally unknown gene, actVI-ORFA. We have characterized an ActVI-ORFA disruptant by functional complementation and reverse transcriptase polymerase chain reaction analysis of the expression profiles of the act genes. Introduction of the functional actVI-ORFA gene into the disruptant restored actinorhodin production to an extent similar to that seen in the wild-type cells and abolished the accumulation of actinorhodin biosynthetic intermediates and shunt products specific for actVI mutants. Thus, unique phenotypes observed in the mutant are solely dependent on the function of actVI-ORFA. The disruptant was shown to yield significantly lower levels of the transcripts for certain act genes, especially for the actVI-ORF1-VA-ORF2 transcription unit, leading to the accumulation of the intermediates and shunt products. The functional actVI-ORFA gene restored expression of actVI-ORF1, which encodes a key reductase in the actinorhodin tailoring step, in the mutant cells, indicating a possible regulatory role of ActVI-ORFA.

Functional studies on a ketoreductase gene from Streptomyces sp. AM-7161 to control the stereochemistry in medermycin biosynthesis

Medermycin shows the same trans (3S,15R) configuration as actinorhodin in the pyran ring crucial for its bioactivity. One medermycin biosynthetic gene, med-ORF12, is assumed to be involved in the stereochemical control at C-3. Functional complementation suggested that it plays a similar role as actVI-ORF1 previously proved to determine the stereospecificity at C-3 in actinorhodin biosynthesis. Co-expression of med-ORF12 with actinorhodin early biosynthetic genes further demonstrated that med-ORF12 encodes a ketoreductase responsible for the enantioselective reduction at C-3 in the formation of the pyran ring.

Remarkably different structures and reaction mechanisms of ketoreductases for the opposite stereochemical control in the biosynthesis of BIQ antibiotics

Two ketoreductases, RED1 and RED2, are involved in the biosynthesis of actinorhodin in Streptomyces coelicolor A3(2) and dihydrogranaticin in S. violaceoruber Tu22, respectively. They are responsible for the stereospecific reductions of the bicyclic intermediate to give (S)- or (R)-DNPA, although there is no similarity between their amino acid sequences. Biotransformation using synthetic analogous substrates revealed that the substrate specificities are quite different. Homology modelling studies and site directed mutagenesis showed remarkable differences in three-dimensional structures and catalytic mechanisms between RED1 and RED2.